
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. demonstrates a strong positive outlook due to its successful engagement with the FDA, where it clarified a potential pathway for the accelerated approval of its lead candidate, OST-HER2, in treating metastatic osteosarcoma. Additionally, the company achieved full regulatory alignment with the UK MHRA, marking a significant milestone that enhances its prospects for conditional approval in the UK market. The emphasis on leveraging immune-response biomarker data from both canine and human trials supports the company’s innovative approach and positions it favorably within the biopharmaceutical landscape.
Bears say
OS Therapies Inc's focus on developing treatments for osteosarcoma faces significant scientific challenges, as the disease does not respond well to receptor-level HER2 inhibition, which undermines the effectiveness of potential therapies. Furthermore, osteosarcoma is characterized as immunologically "cold," genetically unstable, and poorly responsive to antibody-based treatments, which raises concerns about the viability of the company's drug development pipeline. These fundamental issues in addressing the specific nature of osteosarcoma could hinder the company's ability to achieve successful commercialization and attract investor confidence.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares